Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil.
We report a 21-year-old male with childhood-onset familial nephrotic syndrome and frequent relapses who manifested toxicity or treatment resistance to corticosteroids, cyclophosphamide, cyclosporin-A, and tacrolimus. Monotherapy with mycophenolate mofetil (MMF) resulted in maintenance of clinical remission for 14 months without noticeable toxicity, while allowing resolution of steroid-induced side effects. Our observation suggests that MMF may be useful in maintaining remission in nephrotic patients who manifest toxicity to standard immunosuppressive agents.
Chandra
M
M
Department of Pediatrics, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA.
Susin
M
M
Abitbol
C
C
D002675:Child, Preschool; D004351:Drug Resistance; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D019233:Retreatment
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid